Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia
This study has been completed.
Sponsor:
Astellas Pharma Inc
Collaborators:
Cell Pathways
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00036257
First received: May 8, 2002
Last updated: October 14, 2011
Last verified: October 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | April 2003 |
| Estimated Primary Completion Date: | No date given |